rethinkTHC Search
Menu
Study breakdown

Cannabis-Positive ER Tests in Israel Rose Modestly Despite Prescription Surge

Retrospective CohortModerate evidence
The takeaway

Despite an exponential increase in cannabis prescriptions, cannabis-positive urine tests in Israeli ERs rose only modestly from 15.4% to 17.6% over eight years.

Medical cannabis policy analysts, emergency medicine researchers, Israeli health policymakers

Cannabis-positive ER tests: modest rise from 15.4% to 17.6% despite prescription surge

What the researchers found

Among 20,022 urine toxicology tests from Israeli ER admissions (2016-2024), cannabis-positive results increased modestly from 15.4% to 17.6%. The most significant increase (16.6% to 22.4%) occurred in the 25-64 age group. Male sex, younger age, and Israeli-born status predicted positive results.

Why it matters

Israel has one of the world's largest medical cannabis programs. Tracking whether prescription expansion translates to increased ER presentations helps assess population-level impacts of medical access policies.

The numbers in context

20,022 urine tests analyzed. Cannabis-positive rate: 15.4% (2016) to 17.6% (2024). Ages 25-64: 16.6% to 22.4%. Male sex OR=1.5, age <25 OR=4.1, Israeli-born OR=1.3. Co-positive for opioids OR=1.4, MDMA OR=1.8.

How the study worked

Retrospective analysis of urine toxicology screening data from 20,022 emergency department admissions at a large Israeli tertiary medical center from 2016 to 2024.

What this study cannot tell us

Toxicology screens were ordered based on clinical suspicion, not universally, creating selection bias. No diagnostic information about why patients were in the ER. Cannot distinguish medical from recreational cannabis use. Single-center data.

How to read the evidence

Large single-center dataset spanning 8 years, but clinical suspicion-based testing creates significant selection bias.

When this study was published

2025 study with data through June 2024 from an Israeli medical center.

The bigger picture

The modest increase despite a prescription surge suggests that medical cannabis expansion does not necessarily lead to proportional increases in ER-presenting cannabis-related problems, a finding relevant to policy debates worldwide.

Questions still open

  • Why didn't the prescription surge produce a larger increase in positive tests? Are medical cannabis patients less likely to present to ERs? Does clinical suspicion-based screening miss many cannabis-positive patients?

Common questions

Does medical cannabis expansion lead to more ER visits?
In Israel, where cannabis prescriptions surged over this period, cannabis-positive ER tests increased only modestly (15.4% to 17.6%), suggesting the relationship between medical access and emergency presentations is more nuanced than a simple increase.
Who tests positive for cannabis in Israeli ERs?
Young adults under 25 had the highest odds (4.1x), followed by males (1.5x) and Israeli-born individuals (1.3x). Those also positive for other substances like MDMA (1.8x) and opioids (1.4x) were more likely to test positive.

Read the original research

Trends in urine screening positive for cannabis of emergency department admissions in Israel 2016-2024.

Journal of cannabis research, 8(1), 14

Citation

Miron, Oren; Zeltser, David; Schreiber, Shaul; Adelson, Miriam; Peles, Einat. (2025). Trends in urine screening positive for cannabis of emergency department admissions in Israel 2016-2024.. Journal of cannabis research, 8(1), 14. https://doi.org/10.1186/s42238-025-00379-4

Explore the wider topic